Weight-loss drugs show signs of slowing biological aging, say drugmakers

Weight‑loss drugs that target the GLP‑1 peptide, such as Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide, appear to lower patients’ biological age, according to measurements taken with molecular aging clocks. These clocks estimate age from DNA changes or key protein concentrations and showed that overweight or diabetic individuals who received the medications had a reduction of two to three years in biological age compared with a placebo group, although the magnitude varied by clock type and organ examined. In some cases, heart‑protein‑based clocks indicated a slowdown of up to four years. The studies, presented at the Aging Research & Drug Discovery conference, also reinforced the usefulness of these clocks as biomarkers by demonstrating that they respond to pharmacological interventions with proven systemic effects, such as improved kidney function, lowered blood pressure, and reduced mortality.

These findings are significant because they suggest that GLP‑1 agents could act as geroprotectors—drugs that slow or even reverse aging processes—opening the door to therapies that extend healthspan and lifespan. The evidence also strengthens research into aging biomarkers, a necessary step for validating future anti‑aging drugs. Dataqbs, through its open‑garage project, is exploring how AI can accelerate the identification of useful biomarkers in longevity medicine.

Read the original article on MIT Technology Review

This summary is an informational synthesis produced by dataqbs.com. All rights to the original content belong to its author and the cited media outlet. We act solely as curators of technology news and claim no authorship.